2024 Advanced Prostate Cancer Consensus Conference (APCCC)

Viewing 1-20 of 58 articles

APCCC 2024: Patient Selection for Radioligand Therapy: How to Do It in Clinical Practice and How to Decide on the Number of Cycles.

APCCC 2024: Dosing of Radioligand Therapy in Special Situations And/or Toxicity

APCCC 2024: Ideal Monitoring of Patients with mHSPC – What Is Recommended in Daily Clinical Practice?

APCCC 2024: Testosterone Recovery After Stopping ADT – Who Is at Risk for Long-Term Non-Recovery?

APCCC 2024: The Importance of Bone Protection

APCCC 2024: Hot Flushes – How Can We Help Our Patients?

APCCC 2024: Gynecomastia – How to Assess and Treat?

APCCC 2024: How Do We Modify the Diagnostic Pathway to Deal with Rising Rates of Prostate Cancer in Africa?

APCCC 2024: How to Select ADT and an ARPI Based on Cardiovascular Risk Profile

APCCC 2024: Dealing with Inequality – What Can We Learn from the Indian Healthcare System

APCCC 2024: Dealing with Inequality – What Can We Learn from the Brazilian Unified Healthcare System (SUS): Opportunities for Big Data Mining and System Remodeling

APCCC 2024: How to Deal with the Projected Rise of Prostate Cancer Cases in the Chinese Healthcare System

APCCC 2024: Dealing with Inequality – the Promise and Pitfalls for Social Media and AI for Prostate Cancer in Disadvantaged Populations

APCCC 2024: How to Identify Aggressive Variant Prostate Cancer?

APCCC 2024: How to Utilize Presence or Absence of CT Findings on a PSMA PET/CT?

APCCC 2024: Who Should Receive Chemotherapy Before PSMA Radioligand Therapy?

APCCC 2024: Alternative PSMA Ligands for Diagnostics and Treatment – Are They Interchangeable?

APCCC 2024: PARP Inhibition Dissected – in Which DNA Repair Gene Alterations Works Which PARP Inhibitor?

APCCC 2024: How Do We Maximize Use of Radiotherapy for Prostate Cancer in Africa

APCCC 2024: The Best Use of PARP Inhibitors in mCRPC

1
2
3